Consistently, a recent systematic review and network pharmacology analysis confirmed the pivotal roles of the PI3K/AKT/mTOR and JNK signaling pathways in psoriasis and identified EGFR, Sortilin, and Cyr61 as essential molecular hubs, suggesting that targeting these pathways may provide promising therapeutic benefits [13,14]. Here, AKT1 is linked to psoriasis.